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Red cell alloimmunization may induce severe hemolytic sideeffects. Identification of risk-modifying conditions will help tailorpreventative strategies. This study aims to quantify the associa-
tions of hematologic malignancies and solid cancers with red cell alloim-
munization in patients receiving red cell transfusions. We performed a
nested multicenter case-control study in a source population of 24,063
patients receiving their first and subsequent red cell transfusions during
an 8-year follow-up period. Cases (n=505), defined as patients develop-
ing a first transfusion-induced red cell alloantibody, were each com-
pared with 2 non-alloimmunized controls (n=1010) who received a sim-
ilar number of red cell units. Using multivariate logistic regression analy-
ses, we evaluated the association of various malignancies and treatment
regimens with alloimmunization during a delineated 5-week risk peri-
od. The incidence of alloimmunization among patients with acute
(myeloid or lymphoid) leukemia and mature (B- or T-cell) lymphoma
was significantly reduced  compared to patients without these malig-
nancies: adjusted relative risks (RR) with 95% confidence interval (CI)
0.36 (range 0.19-0.68) and 0.30 (range 0.12-0.81). Associations were pri-
marily explained by immunosuppressive treatments [RR for (any type
of) chemotherapy combined with immunotherapy 0.27 (95%CI: 0.09-
0.83)]. Alloimmunization risks were similarly diminished in allogeneic
or autologous stem cell transplanted patients (RR 0.34, 95%CI: 0.16-
0.74), at least during the six months post transplant. Alloimmunization
risks of patients with other hematologic diseases or solid cancers, and
their associated treatment regimens were similar to risks in the general
transfused population. Our findings suggest that, in contrast to malig-
nancies in general, hemato-oncological patients treated with dose-inten-
sive regimens have strongly diminished risk of red cell alloimmuniza-
tion.
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ABSTRACT
Introduction
Transfusion of red cells exposes recipients to non-self
antigens and, consequently, may induce alloantibody for-
mation. Although prior alloimmunization requires the
exclusive administration of donor blood that is negative
for the cognate antigen, accidental re-exposure may
induce severe hemolytic transfusion reactions.1,2
Prevention of alloimmunization and its consequences is
promoted by transfusion of ABO/RhD compatible units to
all red cell recipients. In addition, matching beyond those
antigens is recommended for certain patients considered
to be at high risk of alloimmunization due to repeated
exposure, since the number of transfusions is strongly
associated with the likelihood of alloimmunization.3-5 As
such, in several high-income countries, patients with
hemoglobinopathies and with myelodysplastic syndrome
(MDS), who often face regular transfusions over long peri-
ods of time, receive red cell units matched for the most
immunogenic and clinically relevant antigens C, c, E, e,
and K.3,4 
The ability of the recipient’s immune system to evoke
a humoral alloimmune response upon red cell alloantigen
exposure is likely modulated by his or her clinical condi-
tion.6-8 In this regard, while oncological patients were sug-
gested to have a similar alloimmunization risk to the gen-
eral transfused population,9-11 some studies reported high
incidences of alloimmunization among MDS patients.12,13
Importantly, apart from the study by Sanz et al.,13 these
reports did not take into account the cumulative red cell
exposure, which in the oncological patient population is
often considerable and a main determinant of alloimmu-
nization.5 Therefore, the possible influence of disease-
specific features remains to be clarified. In addition, can-
cer types differ from one another in their intrinsic
immunobiological characteristics as well as in the
immunosuppressive nature of their treatments.
Therefore, alloimmunization rates observed in a hetero-
geneous oncological patient population cannot be extrap-
olated to specific diseases.
Here we report the results of a nested case-control study
quantifying the associations of various hematologic malig-
nancies and solid cancers with the risk of red cell alloim-
munization in a cohort of red cell transfusion recipients.
Methods
Study design and setting
We performed a nested case-control study within a mainly
Caucasian source population of patients receiving their first and
subsequent red cell transfusion between 2005 and 2013 at one of
six Dutch  hospitals. All six hospitals treat patients diagnosed with
oncological pathologies; treatment includes standard remission-
induction chemotherapy for acute leukemia patients. Allogeneic
hematopoietic stem cell transplantation (HSCT) is performed at
three and autologous HSCT at four of these centers.
Details of the source population, including eligibility criteria,
study period per hospital, and the methods adopted have been
published  previously5,14,15 (see  the Online Supplementary Appendix
for details).  
Briefly, cases were all patients who developed a first transfu-
sion-induced alloantibody against c, C, e, E, K, Cw, Fya, Fyb, Jka, Jkb,
Lua, Lub, M, N, S, or s. For all cases, we assumed the last antigen
mismatched transfusion preceding the first positive screen (the
‘Nth’ transfusion) to have been likely to elicit alloimmunization
and defined this as the implicated transfusion. If, due to incom-
plete donor typing, this last mismatched transfusion could not be
identified, the last non-tested unit preceding the first positive
screen was considered as the implicated transfusion. For each case,
we then randomly sampled 2 non-alloimmunized controls on the
pre-condition that these patients received at least N or more trans-
fusions at the same hospital, hereby following an ‘incidence-den-
sity sampling strategy’.16 After marking the Nth transfusion in the
2 matched controls, we subsequently constructed a so-called
‘alloimmunization risk period’ in both the case and the 2 controls,
which stretches from 30 days before to seven days after this Nth
(implicated) transfusion (Figure 1).15 Next, hospital electronic labo-
ratory information systems and patient medical charts were con-
sulted to record  the presence of various clinical conditions during
this period. 
The study protocol was approved by the Ethical Review Board
in Leiden and by the board of each participating center. 
Malignancies and their treatments
We used internationally approved response criteria to define the
remission state of various hematologic malignancies.17-21
Malignancies in complete remission during the alloimmunization
risk period were considered as absent. The presence of minimal
residual disease was not taken into account. All medication under
subcategory L01 in the World Health Organization’s Anatomic
Therapeutic Chemical (ATC) classification index22 was defined as
chemotherapy, with the exception of agents in the pharmacologi-
cal subgroup L01XC, as these involve monoclonal antibodies.
Within subgroups L01XC and L04AA, we defined rituximab,
alemtuzumab, and rabbit- or horse-derived anti-thymocyte globu-
lin (ATG) as anti-lymphocyte immunotherapy. 
Statistical analysis
Multiple imputation was used to account for missing data.
Potential confounders were identified on the basis of their associ-
ation with the assessed determinant among the source population
(i.e. the non-alloimmunized controls). 
Using multivariate logistic regression analyses conditioning on
the matched variables and on the identified potential confounders,
we evaluated the associations of various hematologic malignan-
cies and solid cancers, treatment modalities, and degree of
leukopenia with the development of red cell alloimmunization. 
As we used an incidence-density sampling procedure to select
controls,16 all odds ratios are presented as relative risks (RRs).23,24 
Further details on the statistical analytical methods adopted are
provided in the Online Supplementary Appendix.
Results
Among 54,347 newly-transfused patients, 24,063 met all
study criteria. The majority of excluded patients were inel-
igible due to the absence of an antibody screen following
a single transfusion episode (n=25,037). 
First-formed red cell alloantibodies were identified in
505 patients (2.1%) (Online Supplementary Table S1).
Thirty-seven of those patients (7.3%), including 21 of 32
(65.6%) who formed anti-Lua, only received units for
which testing of the cognate antigen had not been per-
formed; we assumed the last non-tested unit preceding the
first positive screen to have elicited alloimmunization. 
General and clinical characteristics of the 505 alloimmu-
nized patients and their 1010 matched control subjects are
presented in Online Supplementary Tables S1 and S2. 
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Malignancies present during the alloimmunization 
risk period
A total of 606 patients (40.0%) had at least one type of
malignancy (270 had a hematologic malignancy and 338 a
solid tumor; 2 patients presented with both types of
malignancies). Online Supplementary Table S3 presents
types and subtypes of malignancies.
The presence of a malignancy could not be confirmed
for 12 patients: 4 patients with a clinical condition suspect-
ed for a malignancy that was not further evaluated, 4
patients with a suspected malignancy in whom a malig-
nancy was later confirmed, and 4 patients receiving treat-
ment for a solid tumor for whom the remission status at
the time of the risk period was unclear. These 12 patients
were not included in the corresponding analyses. 
Online Supplementary Tables S4 and S5 show identified
confounders for each type of malignancy. Control patients
with acute leukemia and lymphoma, as compared to con-
trol patients without these diseases, were younger and
had less comorbidity (including renal insufficiency and
presence of other malignancies). They more frequently
received chemotherapy and immunosuppressant medica-
tion and more frequently had decreased leukocyte counts. 
Maximum frequency of missing data per identified con-
founder was 2.7% (Online Supplementary Table S6). 
The association between types of malignancies 
and red cell alloimmunization 
Table 2 presents the number of cases and controls
according to various types of malignancies. Acute
leukemia was present in 14 cases (2.8%) compared to 74
(7.3%) controls. There was a reduced incidence of red cell
alloimmunization in patients with acute (myeloid or lym-
phoblastic) leukemia and in patients with mature (B- or T-
cell) lymphoma  [adjusted RR 0.36 (95%CI: 0.19-0.68) and
0.30 (95%CI: 0.12-0.81), respectively]. Conversely,
patients with chronic lymphocytic leukemia (CLL)
showed a modest, albeit statistically non-significant,
increased risk [adjusted RR 1.20 (95%CI: 0.36-3.93)]. No
association between the other types of malignancies and
red cell alloimmunization was observed, including MDS
and solid malignancies. Similarly, subtypes of solid tumors
were not associated to red cell alloimmunization,
although some RRs presented with wide 95% CIs (Online
Supplementary Table S7). As extensive matching recom-
mendations have only been introduced in the Netherlands
since 2011,3 only one of 64 patients (1.6%) with MDS
received CcEe- and K-matched units. 
Effects were similar in all six hospitals (data not shown). 
The association between treatment modalities 
and red cell alloimmunization 
A total of 290 patients received chemo- and/or (anti-
lymphocyte) immunotherapy during the implicated risk
period. Use of any type of chemotherapy without
immunotherapy was not associated with red cell alloim-
munization. However, when regimens included lympho-
cyte-targeted monoclonal antibodies the adjusted RR was
0.27 (95%CI: 0.09-0.83) (Table 3). Twenty-five of the 49
patients (51%) treated with monoclonal antibodies
received ATG (with or without alemtuzumab) for in vivo
depletion of T cells in the context of an allogeneic HSCT
(n=21), aplastic anemia (n=3), or combined pancreas-kid-
ney organ transplant (n=1). 
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Table 1. Patients' characteristics during the alloimmunization risk period.
Characteristics                                     Cases                       Controls
                                                           (N=505)                     (N=1010)
Men                                                              237 (46.9)                        568 (56.2)
Age in years (median, IQR)               67.0 (55.0-75.9)              65.3 (51.6-75.1)
Cumulative number of red cell                       
units received (median, IQR)
Over lifetime*                                            4 (2-8)                              4 (2-8)
During risk period                                     3 (2-6)                              4 (2-8)
Days transfused during                              1 (1-3)                              2 (1-3)
risk period (median, IQR)                               
Values are number (N) (%), unless otherwise stated. IQR: interquartile range. *Up
until the first positive screen for cases and up until the last available (negative) screen
for controls.  
Table 2. Association between various malignancies and red cell alloimmunization. 
Cases Controls RR (CI)* Adjusted RR (CI)† Excluded 
(N=505) (N=1010) from analysis
Hematologic malignancies
Acute leukemia 14 (2.8) 74 (7.3) 0.31 (0.17-0.58) 0.36 (0.19-0.68) 1
Myeloid 14 (2.8) 62 (6.1) 0.38 (0.20-0.71) 0.41 (0.22-0.79) 0
Lymphoblastic‡ 0 (0) 12 (1.2) 0.00 (NC) 0.00 (NC) 1
Myelodysplastic syndrome§ 18 (3.6) 46 (4.6) 0.76 (0.43-1.36) 0.75 (0.41-1.36) 2
Multiple myeloma 10 (2.0) 26 (2.6) 0.77 (0.36-1.62) 0.79 (0.36-1.71) 0
Myeloproliferative neoplasm|| 9 (1.8) 29 (2.9) 0.62 (0.29-1.33) 0.64 (0.29-1.41) 0
Chronic lymphocytic leukemia 5 (1.0) 7 (0.7) 1.45 (0.45-4.67) 1.20 (0.36-3.93) 0
Lymphoma¶
All 5 (1.0) 35 (3.5) 0.27 (0.10-0.69) 0.30 (0.12-0.81) 2
(Mature) B-cell lymphoma 4 (0.8) 28 (2.8) 0.27 (0.09-0.77) 0.30 (0.10-0.89) 2
T-cell lymphoma 1 (0.2) 6 (0.6) 0.33 (0.04-2.75) 0.37 (0.04-3.15) 2
Non-hematologic malignancies
Carcinoma 112 (22.3) 183 (18.2) 1.30 (0.99-1.70) 1.01 (0.75-1.37) 7
Other 12 (2.4) 31 (3.1) 0.77 (0.39-1.53) 0.83 (0.41-1.68) 1
Values are expressed as number (N) (%). *Adjusted for the matched variables: number of transfused red cell units and hospital. †Additionally adjusted for other potential con-
founders (for details, see Online Supplementary Table S5). ‡Acute lymphoblastic leukemia and acute lymphoblastic lymphoma. §Six patients were diagnosed with a myelodys-
plastic syndrome in combination with another hemato-oncological disorder. ||Including polycythemia vera, essential thrombocytosis, primary myelofibrosis, juvenile and chronic
myelomonocytic leukemia. ¶One patient was diagnosed with an undifferentiated mature lymphoma. RR: relative risk; NC: not computable. 
Patients receiving chemotherapeutic agents for acute
leukemia or lymphoma during the implicated risk period
had substantially reduced alloimmunization incidences
[RR 0.29 (95%CI: 0.14-0.60) and 0.08 (95%CI: 0.01-0.57),
respectively]. This reduction in risk did not seem to be fur-
ther influenced to any great extent by the time interval
between the initial diagnosis and the period of risk (data
not shown). In contrast, non-treated patients with these dis-
orders demonstrated risks comparable to the remainder of
the patient population (Table 4). Sixty-two of the 74 treat-
ed patients (84%) with acute leukemia received induction
therapy during the alloimmunization risk period.
Analogous to acute leukemia and mature lymphoma, the
22 patients who received treatment for MDS (including 13
patients receiving induction therapy and 7 receiving
hypomethylating agents), demonstrated a trend towards
reduced alloimmunization incidences [RR 0.31 (95%CI:
0.09-1.06)] (Table 4). Chemotherapy did not have any
impact on risks in patients with other types of hematolog-
ic malignancies or carcinoma (Table 4 and Online
Supplementary Table S8). 
A total of 54 patients received radiotherapy (of any dose
and frequency), including 10 patients who received total
body irradiation in the setting of an allogeneic HSCT.
Radiotherapy was not associated with red cell alloimmu-
nization (Table 3). 
Respectively 51, 13, and 10 patients underwent an allo-
geneic HSCT, an autologous HSCT, or both before or dur-
ing the risk period. In 51 patients, a reduced-intensity allo-
geneic HSCT conditioning regimen was followed (includ-
ing 8 patients who received a double cord transplant),
while 10 patients received a myeloablative conditioning
regimen. Alloimmunization incidences were substantially
decreased in these allogeneic or autologous stem cell
transplant recipients [RR 0.34, (95%CI: 0.16-0.74)], at least
during the first six months after transplant (Table 3). There
was no difference in alloimmunization risk between recip-
ients of an autologous or allogeneic HSCT (data not shown). 
Finally, the degree of leukopenia was strongly associat-
ed with diminished red cell alloimmunization (Table 5).
Here, patients with leukocyte counts of less than 1.0x109/L
demonstrated an adjusted RR of 0.33 (95%CI: 0.20-0.55).
Similar results were obtained when we restricted these
analyses to leukocyte counts determined within the week
following the implicated transfusion (Table 5). The degree
of leukopenia was associated with the type of malignancy
and whether or not the patient received chemotherapy. In
this regard, minimum leukocyte counts of less than
1.0x109/L were observed respectively in 66.2%, 75.9%,
and 13.8% of patients with acute leukemia, lymphoma,
and carcinoma receiving chemotherapy during the risk
period (P<0.0001 for carcinoma vs. acute leukemia and for
carcinoma vs. lymphoma). 
Discussion
In this nested case-control study, we evaluated whether
patients diagnosed with hematologic malignancies and
solid cancers differed from the general transfused patient
population with regards to the risk of forming red cell
alloantibodies. Patients treated for acute leukemia (of
either  myeloid or lymphoblastic origin) and patients with
mature (B- or T-cell) lymphomas demonstrated a 3-fold
decrease in the incidence of clinically relevant alloantibod-
ies against red cell alloantigens. In contrast, the alloimmu-
nization incidence among patients treated for other hema-
tologic malignancies or solid tumors was similar to those
among the non-malignant patient population. 
Although earlier reports only observed similar or even
increased red cell alloimmunization frequencies in the
oncological patient population,9-11 these prevalence-based
studies did not adjust for the substantial number of trans-
fusions these patients usually receive. However, it is well
known that the cumulative transfusion dose is an impor-
tant determinant of alloimmunization.5 Consequently, the
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Figure 1. Illustration of the alloimmunization risk period. For each case, the last antigen mismatched transfusion preceding the first serological detection of an
alloantibody was defined as the ‘implicated (Nth) transfusion’ since this transfusion most likely triggered alloimmunization. Alloimmunizations within seven days of
the first antigen mismatched transfusion were not taken into consideration as these most likely represented boosting rather than primary alloimmunizations. An
alloimmunization risk period was then constructed starting 30 days before and finishing seven days after the defined implicated transfusion. Subsequently, for each
case, 2 controls who received at least the same number of red cell units were randomly selected and a similar alloimmunization risk period was constructed around
the Nth transfusion.  In this example, as the fourth red cell unit most likely elicited red cell alloimmunization, the alloimmunization risk period in both the case and
control was constructed around the fourth transfusion. Figure adapted from: Evers et al.15
observed positive associations might have been due to the
quite intensive red cell transfusion support that is general-
ly needed in the treatment of certain malignancies rather
than to disease-specific characteristics. So far, no studies
have compared specific oncological diseases for alloimmu-
nization risks. 
Our findings suggest that especially the dose-intensive
immunosuppressive therapy influences alloimmunization.
This seems biologically plausible. Several classical cyto-
toxic agents frequently used in the treatment of acute
leukemia and lymphoma, including cyclophosphamide,
purine nucleoside analogs, and anthracyclines, are known
to induce prolonged (mainly naïve) CD4+ T-cell and B-cell
depletion.25-28 Moreover, chemotherapeutic regimens often
include corticosteroids, a class of immunosuppressants
which we earlier reported  to protect against red cell
alloimmunization.8 Significantly reduced incidence of red
cell alloimmunization was also found in patients receiving
anti-lymphocyte targeted agents (i.e. ATG, alemtuzumab,
and rituximab). ATG is well known for its strong and pro-
longed T-cell depleting effects.29,30 In addition, ATG prepa-
rations contain antibodies against several B- and even plas-
ma cell-specific markers.30,31 In agreement with this, eradi-
cation of B cells by rituximab has been shown to coincide
with impaired primary as well as re-call vaccine
responses.32-35 Finally, we observed profoundly lower
alloimmunization rates in the setting of HSCT, either
autologous or allogeneic, which appeared to be sustained
at least during the first six months after transplant. Even
though we cannot fully exclude the possibility that the 8
cases of alloimmunization following an allogeneic HSCT
could  have been elicited by donor-recipient red cell anti-
gen mismatches (in addition to exposure via transfusion),
these findings are consistent with previous studies report-
ing anti-D formation to be rare in RhD-negative HSCT
recipients exposed to RhD.36-38 Reconstitution of adaptive
immune cells generally takes up to 6-12 months following
HSCT,39-44 depending on age-associated thymic function-
ing, type of stem cell harvest, and intensity of T-cell deple-
tion strategies, while humoral immunity may continue to
be deficient even after several years.45,46
Although treatment-induced immunosuppression
seems to be  the principle explanation for our observa-
tions, other non-measured factors associated with receiv-
ing treatment (e.g. co-morbidities and disease stage) might
have interacted with disease-specific effects on the
immune response. Therefore, we cannot exclude the pos-
sibility that part of the observed effects could be directly
related to the diseases themselves, i.e. induction of an
immunosuppressive but tumor tolerant state via host
immune evasion mechanisms of malignant cells.47-50
Furthermore, as patients received a wide range of differ-
ent chemotherapeutic regimens at varying times before
the alloimmunization risk period, it is not possible to
come to any firm conclusions as to  whether or to what
extent patients in complete remission of their treated
malignancy should be considered to be significantly
immunosuppressed. As such, our  RRs might underesti-
mate true effects and our results do not preclude the pos-
sibility that these patients have a diminished red cell
alloimmunization risk. 
In contrast to some other studies,12,13 our incidence-
based analysis did not demonstrate an enhanced alloim-
munization susceptibility with a diagnosis of MDS.
However, and similar to intensively treated patients with
acute leukemia and mature lymphoma, patients who
received treatment for their MDS tended to show inci-
dence of reduced alloimmunization. Consequently, the
decision to transfuse extended donor-matched products to
this patient population should not be based on the MDS
diagnosis itself, but on other factors associated to an
increased alloimmune response, e.g. a high transfusion
burden. 
Finally, the alloimmunization RR in patients with chron-
ic lymphocytic leukemia (CLL) independent of their treat-
ment seemed to be increased compared to lymphoma
patients, although we acknowledge that the number of
CLL patients in the current study is not sufficient to con-
D. Evers et al.
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Table 3. Treatment modalities and red cell alloimmunization risks. 
Cases Controls RR (CI)* Adjusted RR (CI)† Excluded
(N=505) (N=1010) from analysis
Chemo- and/or immunotherapy 6
Type
None 437 (86.9) 782 (77.7) ref ref
(Only) chemotherapy‡ 61 (12.1) 180 (17.9) 0.57 (0.41-0.79) 0.86 (0.54-1.36)
(Only) immunotherapy§ 1 (0.2) 4 (0.4) 0.57 (0.06-5.67) 0.62  (0.07-5.18)
Chemo- and immunotherapy 4 (0.8) 40 (4.0) 0.17 (0.06-0.48) 0.27 (0.09-0.83)
HSCT 0
Type
Autologous or allogeneic || 10 (2.0) 64 (6.3) 0.29 (0.14-0.58) 0.34 (0.16-0.74)
Timing (months before implicated transfusion)
None 495 (98.0) 946 (93.7) ref ref
0-1 4 (0.8) 27 (2.7) 0.28 (0.09-0.81) 0.34 (0.11-1.07)
>1-6 3 (0.6) 24 (2.4) 0.22 (0.06-0.75) 0.24 (0.07-0.86)
>6 3 (0.6) 13 (1.3) 0.46 (0.13-1.70) 0.55 (0.14-2.09)
Radiotherapy 15 (3.0) 39 (3.9) 0.78 (0.42-1.44) 0.75 (0.39-1.44) 0
Values are expressed as number (N) (%). *Adjusted for the matched variables: number of transfused red cell units and hospital. †Additionally adjusted for other potential con-
founders (for details, see Online Supplementary Table S5). ‡All medication under subcategory L01 within the Anatomical Therapeutic Chemical (ATC) classification index with
the exception of monoclonal antibodies. §Monoclonal antibodies directed against B- and/or T-lymphocyte markers received by 49 patients (rituximab n=20, alemtuzumab n=5,
and anti-thymocyte globulin n=25). ||10 patients received an allogeneic stem cell transplant after an earlier autologous HSCT; RR: relative risk; CI: confidence interval;  HSCT:
hematopoietic stem cell transplant (either autologous or allogeneic) received before or during the alloimmunization risk period. 
firm such a hypothesis. However, CLL is characterized by
profound immune disturbances including non-clonal for-
mation of IgG auto-antibodies directed against blood cell
antigens.51-53 Observations seem to suggest that the disease
disturbs normal regulatory potential. Seemingly in con-
trast with these findings, antimicrobial vaccination
responses are often compromised in CLL patients.54 
Some final comments regarding our methods are appro-
priate. First, the use of an incidence-density sampling
strategy guaranteed that controls were exposed to at least
the same number of red cell units as their matched
cases.16,55 Given this adjustment for cumulative number of
red cell exposures, our RRs reflect relative risks independ-
ent of exposures. Our alloimmunization risk period was
defined specifically  to provide a comprehensive study of
the influential effect of conditions present around the time
of red cell exposure. As the immunosuppressive effects of
various treatment regimens are slow to wear off, we pre-
ferred to use a relatively long period of risk to precede the
implicated transfusion.  
Second, our strategies do not fully guarantee the exclu-
sion of all boosting events. Actual ‘lag periods’, i.e. the
time needed before antibody levels become detectable
after primary antigen encounter, are currently unknown
and may even differ according to the antigen used.
Regarding our chosen lag period of seven days, we cannot,
therefore, fully exclude the possibility that our study
included patients whose antibody titers became unde-
tectable over time and who quickly demonstrated re-call
responses upon re-exposure to the alloantigen. However,
we had thought that a substantial amount of boosting
reactions as primary alloimmunization events would have
biased our RRs towards the null-effect. However, a sensi-
tivity analysis, in which we excluded the 53 patients in
whom alloantibodies were discovered during the second
week after their first antigen-incompatible transfusion,
showed no change in RRs (data not shown). We are confi-
dent, therefore, that any possible bias deriving from our
choice of lag period is small.
Third, we observed no associations with red cell alloim-
munization other than the above mentioned hematologic
malignancies and specific types of solid malignancies,
Malignancies and red cell alloimmunization
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Table 4. Chemotherapy and red cell alloimmunization risks.
Type of malignancy Chemotherapy Cases Controls RR (CI)* Adjusted RR (CI)†
(N=505) (N=1010)
Acute leukemia
- 489 931 ref ref
+ - 4 10 0.77 (0.22-2.66) 0.88 (0.25-3.09)
+ + 10 64 0.25 (0.12-0.51) 0.29 (0.14-0.60)
Myelodysplastic syndrome
- 484 959 ref ref
+ - 15 28 1.06 (0.54-2.07) 1.04 (0.52-2.06)
+ + 3 18 0.32 (0.09-1.12) 0.31 (0.09-1.06)
Lymphoma
- 498 969 ref ref
+ - 4 7 1.08 (0.31-3.76) 1.26 (0.35-4.51)
+ + 1 28 0.07 (0.01-0.49) 0.08 (0.01-0.57)
Carcinoma
- 390 821 ref ref
+ - 85 141 1.28 (0.95-1.73) 0.99 (0.71-1.38)
+ + 26 39 1.40 (0.84-2.35) 1.14 (0.67-1.94)
+ = present; - = absent. Only numbers of patients for whom the presence or absence of a given malignancy and the use of chemotherapy during the alloimmunization risk period
could be determined are presented. *Adjusted for the matched variables: number of transfused red cell units and hospital. †Additionally adjusted for other potential confounders
(for details, see Online Supplementary Table S5). N: number; RR: relative risk; CI: confidence interval.
Table 5. Leukopenia and red cell alloimmunization risks. 
Minimum leukocyte counts Cases Controls RR (CI)* Adjusted RR (CI)†
(x109/L) during: (N=505) (N=1010)
Alloimmunization risk period‡
4-10 307 524 ref ref
2-<4 61 128 0.82 (0.58-1.15) 0.87 (0.61-1.24)
1-<2 14 43 0.52 (0.27-0.99) 0.59 (0.31-1.13)
<1 26 142 0.27 (0.17-0.44) 0.33 (0.20-0.55)
≤1 week following implicated transfusion
4-10 273 485 ref ref
2-<4 44 107 0.72 (0.47-1.10) 0.80 (0.52-1.23)
1-<2 15 41 0.60 (0.30-1.23) 0.75 (0.36-1.58)
<1 19 119 0.24 (0.13-0.44) 0.34 (0.17-0.66)
Minimum leukocyte counts as measured during the alloimmunization risk period and as measured during the week following the implicated transfusion. Values are expressed
as number (N) (%). Cumulative numbers of presented cases and controls do not necessarily equal the total number of cases and controls, as patients with leukocytosis are not
presented. * Adjusted for the matched variables: number of transfused red cell units and hospital. †Additionally adjusted for other potential confounders (for details, see Online
Supplementary Table S5). ‡P=0.02 for trend analysis. RR: relative risk; CI: confidence interval.
although the low numbers of some of these subgroups and
the consequent wide CIs per RR prevent any firm conclu-
sions to be made. A much larger study or a meta-analysis
of similar studies is needed to assess whether these malig-
nancies are indeed not associated to red cell alloimmuniza-
tion. Also, due to the fact that remission evaluations avail-
able during the alloimmunization risk period were not
always complete, we were unable to assess whether the
disease stage itself is associated to cell alloimmunization.
Finally, since patients treated with chemotherapy received
a wide range of chemotherapeutic agents and combina-
tions, as well as varying dose intensities, we were not able
to quantify risks according to each single agent.
In conclusion, risks associated with red cell alloimmu-
nization are significantly reduced in patients treated for
acute leukemia and mature lymphomas, as well as in
recipients of an autologous or allogeneic HSCT. These
diminished immune responses most likely reflect the
intensity of treatment-associated immunosuppression. In
contrast, alloimmunization risks in patients with other
hematologic diseases and in patients with solid cancers are
similar to those in the general, non-oncological transfused
patient population. These findings clearly indicate that, in
addition to cumulative red cell exposure, disease-specific
conditions should be taken into account when considering
the risk of red cell alloimmunization in order to select
those patients who would most benefit  from extended
matched red cell transfusions.
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